Strategies to improve
chemotherapy in urothelial cancer
To prospectively investigate new chemotherapy combinations in first and second line treatment to improve the outcome (survival, toxicity and quality of life) for patients with metastatic urothelial cancer.
To retrospectively analyze outcome (survival, toxicity and quality of life), predictive prognostic factors in second line metastatic treatment and neoadjuvant chemotherapy in patients with muscle invasive disease to improve the knowledge of optimal chemotherapy treatment in standard clinical practice, and to identify the patients that benefit the most from such treatment.
Main supervisor: Anders Ullén, MD, PhD, Associate Professor, Senior consultant
Co-supervisor: Yvonne Brandberg, Professor, Senior Psychologist, Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.
The fragile bladder cancer patient
- Enrolled at University of Copenhagen by MD, Lise Brehm Høj. Contact: firstname.lastname@example.org
In three studies we investigate different aspects regarding "the fragile bladder cancer patient". In a prospective case-control study we examine the importance of geriatric intervention on adherence to oncological treatment and different aspects of muscle function in patients with disseminated bladder cancer. In two retrospective studies we describe patients with disseminated bladder cancer treated in Denmark in the period January 2010 to March 2016 and patients with disseminated bladder cancer unfit for systemic oncological treatment, respectively.
September 2017 – August 2020
Helle Pappot, Henriette Lindberg
Improved Therapeutic and Evaluation Strategies in Advanced Urothelial Cancer
- MD, Carl-Henrik Shah, contact: email@example.com
The overall aim of this thesis is to improve treatment and treatment evaluation methods in advanced UC. Another focus is to find predictive and prognostic biomarkers to personalise treatment in advanced UC
Patient-reported outcomes in bladder cancer; a randomized trial on the effect on chemotherapy completion
- Enrolled at University of Copenhagen by MD, Gry Assam Taarnhøj, contact: firstname.lastname@example.org
In three clinical trials we aim to assess the feasilibity and effect of using patient-reported outcomes in bladder cancer patients with muscle-invasive disease, T2-T4NxMx, undergoing chemo- or immunotherapy.
April 2017-March 2020
Christoffer Johansen, Helle Pappot, Henriette Lindberg
The Role of Urokinase Receptor in Urothelial Carcinoma of the Bladder
- MD, PhD, Line Hammer Dohn. Contact: email@example.com
The objective of the thesis was to investigate the role of uPAR in invasion and progression of urothelial carcinoma of the bladder with focus on the clinical implications of uPAR in patients treated with radical cystectomy.
- “Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder”. Urol Oncol. 2015 Apr;33(4):165.e15-24. doi: 10.1016/j.urolonc.2014.12.001.
- ”uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications”. PLoS One. 2015 Aug 20;10(8):e0135824. doi: 10.1371/journal.pone.0135824.
- “Preoperative levels of circulating forms of uPAR can predict recurrence and cancer specific death in patients treated with radical cystectomy for urothelial carcinoma of the bladder”. Manuscript in preparation.
November 2012-March 2015
Hans von der Maase, Helle Pappot, Gunilla Høyer-Hansen, Ole Didrik Lærum